The Effect of Raloxifene Treatment on Lipid Profile in Elderly Individuals: A Systematic Review and Meta-analysis of Randomized Clinical Trials

The Effect of Raloxifene Treatment on Lipid Profile in Elderly Individuals: A Systematic Review and Meta-analysis of Randomized Clinical Trials

•Raloxifene decreased TC concentrations in elderly patients.•Raloxifene did not alter TG, HDL-C, and LDL-C levels.•However, there was a non-statistical decrease in LDL-C levels that deserves clinical attention. To perform a systematic review and meta-analysis of randomized clinical trials (RCTs) to...

Full description

Saved in:
Bibliographic Details
Published in:Clinical therapeutics Vol. 43; no. 9; pp. 297 - 317
Main Authors: Shi, Hong, Santos, Heitor O., de Souza, Ivan G.O., Hoilat, Gilles Jadd, Martins, Carlos E.C., Varkaneh, Hamed Kord, Alkhwildi, Joud Amer, Hejji, Aljawhara Talal, Almuqayyid, Faisal, Abu-Zaid, Ahmed
Format: Journal Article
Language:English
Published: Bridgewater Elsevier Inc 01-09-2021
Elsevier Limited
Subjects:
Bias
Biomedical materials
Cholesterol
Clinical trials
Diabetes
Diabetes mellitus
Diabetes mellitus (non-insulin dependent)
elderly
Estrogen receptors
Estrogens
Hemodialysis
High density lipoprotein
Kidney diseases
LDL-C
Lipids
Lipoproteins
Low density lipoprotein
Meta-analysis
Middle age
Older people
Osteoporosis
Raloxifene
Reviews
SERMs
Systematic review
total cholesterol
Triglycerides
Womens health
lipids
raloxifene
SERMs
LDL-C
total cholesterol
elderly
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•Raloxifene decreased TC concentrations in elderly patients.•Raloxifene did not alter TG, HDL-C, and LDL-C levels.•However, there was a non-statistical decrease in LDL-C levels that deserves clinical attention. To perform a systematic review and meta-analysis of randomized clinical trials (RCTs) to elucidate the effects of raloxifene on the lipid profile in elderly individuals. A systematic review and meta-analysis of RCTs was performed following the PRISMA statement. Data on triglycerides (TGs), total cholesterol (TC), HDL-C, and LDL-C were extracted. Relevant publications up to October 2020 were detected through searches in the PubMed/MEDLINE, Web of Science, Scopus, and Embase databases. Changes were reported as weighted mean differences (WMDs) and 95% CIs using random-effects models. Nine studies were selected, with a duration of intervention ranging from 2 and 12 months and a raloxifene dose of 60 to 120 mg/d. Studies were performed in healthy individuals and in those with disorders, such as osteoporosis, type 2 diabetes, and kidney disease required long-term hemodialysis. Overall, TG (WMD, −6.50 mg/dL; 95% CI, −34.18 to 21.20 mg/eL; P = 0.646), LDL-C (WMD, −17.86 mg/dL; 95% CI, −42.44 to 6.72 mg/dL; P = 0.154), and HDL-C (WMD, 2.35 mg/dL; 95% CI, −1.14 to 5.84 mg/dL; P = 0.187) levels did not change significantly after the administration of raloxifene. In contrast, TC levels decreased after raloxifene therapy (WMD, −6.59 mg/dL; 95% CI, −13.13 to −0.05 mg/dL; P = 0.048). Raloxifene therapy decreased TC levels but did not alter TG, HDL-C, and LDL-C concentrations in elderly individuals. Regarding the LDL-C levels, although the finding lacked statistical significance, we believe that there was a mean reduction that deserves further clinical attention as much as TC. [Display omitted]
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Undefined-3
ISSN:0149-2918
1879-114X
DOI:10.1016/j.clinthera.2021.07.017